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Available online 29 August 2015AbstractConstipation is a common problem in the older population. Among other treatment modalities, Epsom salt enema has been used in emer-
gency rooms. Since Epsom salts are 100% magnesium sulfate and excreted wholly through the kidneys, hypermagnesemia may result from their
use, particularly in patients with impaired renal function. A case of fatal iatrogenic hypermagnesemia resulting from the administration of an
Epsom salt enema is presented here. We suggest that magnesium-containing enemas should be avoided in patients with impaired renal function.
Copyright © 2015, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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Hypermagnesemia is a rare but potentially fatal condition if
unrecognized. The majority of reported cases of hyper-
magnesemia are iatrogenic, arising from the administration of
magnesium-containing laxatives or antacids,1e4 magnesium-
containing enemas,5,6 or intravenous magnesium sulfate.7
Magnesium toxicity presents with nonspecific signs and
symptoms8 and is therefore difficult to diagnose based on
clinical findings. We present a case of iatrogenic hyper-
magnesemia resulting from the administration of an Epsom
salt enema.2. Case Report
An 85-year-old woman presented to the emergency
department with a 3-day history of constipation and diffuse
abdominal pain. Her past medical history was significant for
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2211-5587/Copyright © 2015, Taiwan Society of Emergency Medicine. Publishedstage renal disease, gastric angiodysplasia, and anemia. On
presentation, her blood pressure was 147/69 mmHg, and all
other vital signs were normal. Her cardiac, respiratory, and
abdominal examinations were unremarkable. Complete blood
count revealed a hemoglobin level of 99 g/L (120e160 g/L),
with a normal white blood cell and platelets count; pro-
thrombin and partial thromboplastin times were normal; and
urea was 18.6 mmol/L (3.0e7.1 mmol/L), creatinine
972 mmol/L (60e130 mmol/L), sodium 133 mmol/L
(135e145 mmol/L), potassium 4.6 mmol/L (3.5e5.0 mmol/
L), chloride 99 mmol/L (98e110 mmol/L), calcium
2.36 mmol/L (2.14e2.66 mmol/L), phosphate 1.79 mmol/L
(0.89e1.55 mmol/L), and magnesium 0.81 mmol/L
(0.70e1.10 mmol/L). An abdominal X-ray revealed dilated
small bowel loops and a minimally distended colon. No air-
efluid levels or free air was seen.
Shortly after presentation, an enema containing water,
glycerin, and 28 g of Epsom salts (approximately 3 g of
elemental magnesium) was administered, with no evacuation
of stool. Over the subsequent 7 hours, the patient developed
worsening abdominal distension and bowel sounds became
absent. A large ecchymosis appeared on the right side of the
patient's face, accompanied by the onset of rectal and vaginal
bleeding. The patient's neurologic status deteriorated, withby Elsevier Taiwan LLC. All rights reserved.
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flexes, and inability to speak. Breathing became shallow, and
oxygen requirements increased to 10 L on a nonrebreather
mask. Rectal temperature fell to a nadir of 33.8C (Figure 1).
Electrocardiography was performed, which showed first-
degree atrioventricular block (PR interval 218 milliseconds)
and a prolonged QRS interval (118 milliseconds). Piper-
acillinetazobactam was administered due to concern of sepsis,
followed by cryoprecipitate and platelets in an attempt to
correct the bleeding. Blood work drawn 2 hours after the
enema revealed the following: a calcium level of 2.94 mmol/L,
a phosphate level of 1.72 mmol/L, and a magnesium level thatFigure 1. Vital signs in relation to magnesium levels. DBP ¼ diastolic blood presexceeded the detectable range of the assay (>7.8 mmol/L).
Unfortunately, the treating team of physicians was unaware of
these results.
Seven hours after the administration of the magnesium-
containing enema, the consulting internal medicine team
noted the patient's elevated magnesium level. Repeat blood
work confirmed the diagnosis of hypermagnesemia
(>7.8 mmol/L), and revealed normal partial thromboplastin
time (PTT) and International normalised ratio (INR), hemo-
globin level 89 g/L, white blood cell count 10.7  109/L, and
platelet count 139  109/L. The patient was sent urgently for
dialysis. Post dialysis, the patient's oral temperaturesure; HR ¼ heart rat; RR ¼ respiratory rate; SBP ¼ systolic blood pressure.
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prongs. She was alert and speaking, patellar reflexes were
reduced bilaterally, and strength had improved throughout.
Repeat electrocardiography revealed normal sinus rhythm, a
PR interval of 178 milliseconds, and a QRS interval of 84
milliseconds. The postdialysis serum magnesium level was
4.35 mmol/L, and a second hemodialysis treatment on the
same day reduced the magnesium concentration to 2.47 mmol/
L. The patient received hemodialysis every other day for the
management of her end-stage renal disease, and serum mag-
nesium levels gradually normalized. However, the patient
continued to experience fatigue, poor appetite, and muscle
weakness. On Day 9 post admission, the patient declined
further hemodialysis and care was transferred to a palliative
care physician. She died peacefully.
3. Discussion
Renal excretion is the sole route of magnesium elimination8;
therefore, hypermagnesemia most frequently occurs in the
context of renal impairment. However, magnesium toxicity has
also been reported in patients with normal renal function,9 and
impaired gastrointestinal motility has been cited as an addi-
tional risk factor.4,10 In the present case, end-stage renal disease
and impaired intestinal motility were predisposing conditions
for the development of magnesium toxicity. The patient
received approximately 28 g of Epsom salts, which are 100%
magnesium sulfate. This is equivalent to 2.8 g of elemental
magnesium, a considerable amount given that the recom-
mended daily allowance for an adult is 300e400 mg per day.8
Hypermagnesemia presents with nonspecific signs and
symptoms.8 Neurologic effects include lethargy, loss of deep
tendon reflexes, skeletal muscle paralysis, and coma. Cardio-
respiratory effects are bradycardia, hypotension, first-degree
atrioventricular block, QT interval prolongation, respiratory
depression, and ultimately cardiopulmonary arrest. Hyper-
magnesemia has also been associated with paralytic ileus.2
The toxic effects of supraphysiologic magnesium levels are
due to antagonization of calcium-dependent acetylcholine
release at neuromuscular junctions and calcium-channel
blocking effects on cardiac myocytes.8,11 With the exception
of hypotension, bradycardia, and cardiopulmonary collapse,
the patient in the present case report displayed all the afore-
mentioned features of hypermagnesemia.
Several treatment options are available to correct hyper-
magnesemia. Since magnesium competitively binds to cal-
cium channels and hence acts as a calcium-channel blocker,
administration of intravenous calcium can reverse cardiac
arrhythmia, respiratory depression, and hypotension. Adequate
hydration and use of diuretics may help eliminate excess
magnesium through diuresis. Hemodialysis can be lifesaving
in cases of severe toxicity and in patients not responding to
other less invasive measures.
Several aspects of the patient's presentation are noteworthy.
First, the patient became hypothermic shortly after the
administration of the magnesium-sulfate enema. Hypothermia
associated with hypermagnesemia has been describedpreviously1,3; however, it is not widely recognized as a clinical
manifestation of magnesium toxicity. The onset of hyper-
magnesemia in the present report was associated with a
concomitant rise in serum calcium concentration, which has
been reported only twice previously.5,12 This is likely because
of the exchange of calcium at the bone surfaces with mag-
nesium in the circulation.13 In contrast, hypermagnesemia is
more frequently associated with hypocalcaemia,1,6,9 an effect
that is mediated through depression of parathyroid hormone
levels due to hypermagnesemia.14 Finally, the patient devel-
oped significant bruising and bleeding following the onset of
magnesium toxicity. Although uremia and amyloidosis would
have predisposed the patient to bleeding due to platelet and
factor X dysfunction, it is possible that hypermagnesemia may
have been a precipitating factor. This is supported by the
experimental observation that magnesium inhibits platelet
aggregation both in vitro and in vivo.15,163.1. Learning points(1) Iatrogenic hypermagnesemia may be associated with hy-
pothermia, elevated serum calcium levels, and bleeding
diathesis. Hypothermia and hypercalcemia are rare
sequelae of magnesium toxicity.
(2) This case provides additional evidence for avoiding
magnesium-containing enemas in patients with impaired
renal function or gastrointestinal motility disorders.
(3) Physicians should consider tap water or polyethylene
glycol-containing enemas as alternatives in these clinical
contexts.
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